Production of natural killer cell activity-augmenting factor (interleukin-6) by human epiphyseal chondrocytes

Insights into the Roles of Natural Killer Cells in Osteoarthritis

Osteoarthritis (OA) is now widely acknowledged as a low-grade inflammatory condition, in which the intrinsic immune system plays a significant role in its pathogenesis. While the involvement of macrophages and T cells in the development of OA has been extensively reviewed, recent research has provided mounting evidence supporting the crucial contribution of NK cells in both the initiation and advancement of OA. Accumulated evidence has emerged in recent years indicating that NK cells play a critical role in OA development and progression. This review will outline the ongoing understanding of the utility of NK cells in the etiology of OA, focusing on how NK cells interact with chondrocytes, synoviocytes, osteoclasts, and other immune cells to influence the course of OA disease.

Constitutive expression of ligand for natural killer cell NKp44 receptor (NKp44L) by normal human articular chondrocytes

Normal chondrocytes display susceptibility to lysis by natural killer (NK) cells and this phenomenon may play a role in some inflammatory cartilage disorders. The mechanisms of chondrocyte recognition and killing by NK cells remain unclear. Using flow cytometry and immunohistochemical staining we found that normal human articular chondrocytes constitutively express a ligand for NKp44, one of stimulatory NK cell receptors involved in recognition and killing of target cells. Expression of NKp44 ligand by normal articular chondrocytes is not involved in their killing by unstimulated NK cells; however, it is responsible for anti-chondrocyte cytotoxicity mediated by long-term activated NK cells. Thus, expression of NKp44 ligand may play a role in chondrocyte destruction in course of chronic inflammatory cartilage disorders.

Toll-like receptors and chondrocytes: The lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7

OBJECTIVE

To assess the presence of Toll-like receptors (TLRs) 1-9 in human articular cartilage, and to investigate the effects of lipopolysaccharide (LPS)-induced activation of TLR-4 on biosynthetic activity and matrix production by human articular chondrocytes.

METHODS

TLRs 1-9 were assessed in human articular cartilage by reverse transcription-polymerase chain reaction (RT-PCR); TLR-4 was also analyzed by Western blotting and immunohistochemistry. Articular chondrocytes were isolated from human donors and from wild-type or TLR-4(-/-) mice. Chondrocyte monolayer cultures were incubated with interleukin-1beta (IL-1beta) and LPS in the absence or presence of bone morphogenetic protein 7 (BMP-7) and IL-1 receptor antagonist (IL-1Ra). Neosynthesis of sulfated glycosaminoglycans (sGAG) was measured by (35)S-sulfate incorporation. Endogenous gene expression of cartilage markers as well as IL-1beta was examined using RT-PCR. The involvement of p38 kinase or p44/42 kinase (ERK-1/2) in LPS-mediated TLR-4 signaling was investigated by immunoblotting, RT-PCR, and sGAG synthesis.

RESULTS

TLRs 1-9 were found on the messenger RNA (mRNA) level in human articular chondrocytes. The presence of TLR-4 was also observed on the protein level. In murine and human articular chondrocytes, but not in chondrocytes derived from TLR-4(-/-) mice, stimulation with LPS resulted in a decrease in total proteoglycan synthesis. IL-1beta mRNA expression was increased by TLR-4 activation, whereas expression of aggrecan and type II collagen was significantly decreased. The presence of BMP-7 and IL-1Ra antagonized the anti-anabolic effects of LPS. Blocking of p38, but not ERK-1/2, resulted in inhibition of both LPS-mediated IL-1beta gene expression and the negative effects of LPS on matrix biosynthesis.

CONCLUSION

These data demonstrate the presence of TLRs in human articular cartilage. The suppressive effects of LPS on cartilage biosynthetic activity are dependent on the presence of TLR-4, are governed, at least in part, by an up-regulation of IL-1beta, and are mediated by p38 kinase. These in vitro data indicate an anti-anabolic effect of TLR-4 in articular chondrocytes that may hamper cartilage repair in various joint diseases.

Why and How to Use NSAIDs in Osteoarthritis

There is an increasing body of evidence that an inflammatory process can be involved in the development and the progression of osteoarthritis. Such inflammation can be observed at both the cartilage, subchondral bone, and synovial tissue level. Of the 2 main categories of anti-inflammatory drugs [corticosteroids and nonsteroidal anti-inflammatory drugs (NSAIDs)], NSAIDs are the most commonly used oral drugs in osteoarthritis. The symptomatic short-term effect of coxibs is similar to the conventional NSAIDs one and of greater magnitude than the one of analgesics such as paracetamol (acetaminophen). On the basis of current knowledge of potential gastrointestinal and, more importantly, cardiovascular side-effects, the still remaining important question is related to the efficacy-toxicity balance of a chronic systematic daily intake of NSAIDs versus an "at request" (PRN) intake.

Rejection of cartilage formed by transplanted allogeneic chondrocytes: evaluation with monoclonal antibodies

Cellular infiltrates participating in rejection of cartilage formed by transplanted allogeneic rat epiphyseal chondrocytes were evaluated immunohistochemically using a panel of different monoclonal antibodies. One week after transplantation, the grafts were surrounded by numerous class II MHC+ (OX6+, OX17+), CD4+ (W3/25+), and W3/13+ cells as well as some ED1+ monocytes/macrophages. Only a few T (OX19+) and B (HIS14+) cells were present. The number of class II MHC+ cells and ED1+ monocytes/macrophages did not change significantly in the course of rejection whereas the number of CD4+ and W3/13+ cells gradually decreased. On the other hand, there was a significant increase in the number of CD8+ (OX8+) cells. CD8+ cells accumulated close to the transplants and some of them penetrated cartilage matrix suggesting that they might be involved in chondrocyte killing. After 3 months, cartilage was almost completely destroyed and the intensity of infiltrations was markedly decreased. Fibrous connective tissue predominated, however, some class II+ as well as few ED1+, CD4+ and CD8+ cells were still present adjacent to the cartilage remnants. At the time of transplantation, chondrocytes were endowed with RT1.D class II antigen (OX17+), but they did not react with OX6 mAb (monoclonal antibody) recognizing the RT1.B class II molecule. However, after 1 week, some chondrocytes reacted with OX6 mAb and the number of RT1.B positive chondrocytes increased in the course of cartilage rejection.

Mechanism of longitudinal bone growth and its regulation by growth plate chondrocytes

Growth plate chondrocytes play a pivotal role in promoting longitudinal bone growth. The current review represents a brief survey of the phenomena involved in this process at the cellular level; it delineates the contributions made by various activities during the course of the chondrocyte life cycle, notably proliferation and hypertrophy, and illustrates how the relative contributions may be modulated according to the particular needs of an organism at critical phases of growth. The cellular mechanisms by which a few well characterized growth-promoting substances exert their influences are discussed in the light of recent findings pertaining to epiphyseal plate chondrocytes in vivo.

Cytokines in rheumatic diseases

IL-1 and related cytokines have multiple biologic activities relevant to the rheumatic diseases. In addition to mediating inflammatory and immune responses, these proteins regulate many aspects of connective tissue metabolism. The cytokines interact in complex cascades: because of this, and various technical reasons, the exact role of cytokines in the pathogenesis of rheumatic diseases remains uncertain. However, considerable experimental data suggest that the abnormal regulation of cytokines contributes to such siseases as inflammatory arthritis, systemic lupus erythematosus, scleroderma, and dermatomyositis. Animal models of these diseases have contributed to understanding the role of cytokines in pathogenesis. Furthermore, drugs useful in treating these diseases affect cytokine pathways; some cytokines, their antagonists, or related substances have been used therapeutically to treat rheumatic diseases. The therapeutic use of these agents will likely increase as knowledge about the role of cytokines in the pathogenesis of rheumatic diseases expands.